Lundbeck, UMMS to Collaborate on RNAi Therapeutic for Huntington's Disease

Although Lundbeck's foray into the RNAi drugs scene is modest compared with investments made by other pharmas, it comes at a time when many of those firms have put the brakes on their commitment to the approach.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.